Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17525
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGrossmann, Mathis-
dc.date2018-
dc.date.accessioned2018-04-25T23:51:09Z-
dc.date.available2018-04-25T23:51:09Z-
dc.date.issued2018-04-23-
dc.identifier.citationClinical Endocrinology 2018; 89(1): 11-21en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17525-
dc.description.abstractObesity, increasing in prevalence globally, is the clinical condition most strongly associated with lowered testosterone concentrations in men, and presents as one of the strongest predictors of receiving testosterone treatment. While low circulating total testosterone concentrations in modest obesity primarily reflect reduced concentrations of sex hormone binding globulin, more marked obesity can lead to genuine hypothalamic-pituitary-testicular axis (HPT) suppression. HPT axis suppression is likely mediated via pro-inflammatory cytokine and dysregulated leptin signalling and aggravated by associated comorbidities. Whether estradiol-mediated negative hypothalamic-pituitary feedback plays a pathogenic role requires further study. Although the obesity-hypogonadism relationship is bi-directional, the effects of obesity on testosterone concentrations are more substantial than the effects of testosterone on adiposity. In markedly obese men submitted to bariatric surgery, substantial weight loss is very effective in reactivating the HPT axis. In contrast, lifestyle measures are less effective in reducing weight and generally only associated with modest increases in circulating testosterone. In randomised controlled clinical trials (RCTs), testosterone treatment does not reduce body weight, but modestly reduces fat mass and increases muscle mass. Short-term studies have shown that testosterone treatment in carefully selected obese men may have modest benefits on symptoms of androgen deficiency and body composition even additive to diet alone. However, longer-term, larger RCTs designed for patient-important outcomes and potential risks are required. Until such trials are available, testosterone treatment cannot be routinely recommended for men with obesity-associated non-classical hypogonadism. Lifestyle measures or where indicated bariatric surgery to achieve weight loss, and optimisation of comorbidities remain first line. This article is protected by copyright. All rights reserved.en_US
dc.language.isoeng-
dc.subjectandrogenen_US
dc.subjectaromatase inhibitoren_US
dc.subjectestradiolen_US
dc.subjecthypogonadismen_US
dc.subjectkisspeptinen_US
dc.subjectleptinen_US
dc.subjectobesityen_US
dc.subjectselective estrogen receptor modulatoren_US
dc.subjecttestosteroneen_US
dc.titleHypogonadism and Male Obesity: Focus on Unresolved Questions.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleClinical Endocrinologyen_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.identifier.affiliationEndocrinologyen_US
dc.identifier.doi10.1111/cen.13723en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-8261-3457en_US
dc.identifier.pubmedid29683196-
dc.type.austinJournal Article-
local.name.researcherGrossmann, Mathis
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

42
checked on Nov 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.